Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)
暂无分享,去创建一个
K. Nackaerts | T. Owonikoko | D. Spigel | G. Ostoros | C. Baik | T. Csoszi | E. Sheldon-Waniga | D. Huebner | E. Leonard | Z. Márk | T. Csőszi